Non-melanoma Skin Cancer Market

Non-melanoma Skin Cancer Market Outlook from 2024 to 2034

The non-melanoma skin cancer market is estimated to be valued at US$ 5,068.7 million in 2024. The market is expected to register a CAGR of 5.7% from 2024 to 2034. The market is expected to reach a value of US$ 8,859.6 million by 2034.

The number of patients with skin cancer is rising, necessitating skin cancer treatment. The rise in temperatures as a result of global warming is a key reason for the increase in the number of skin cancer patients. The non-melanoma variant of skin cancer is afflicting an increasing number of people, and thus, the market for non-melanoma skin cancer is witnessing a surge in demand.

Key Market Growth Drivers

Unlike melanomas, non-melanoma skin cancer works slowly and thus there is more scope for treatment. With preventive healthcare measures being implemented, non-melanoma skin cancers are being detected at early stages and treatment is being administered for a prolonged period. As such, the results of the treatment are positive, benefitting the market.

Healthcare institutions’ drive awareness about skin cancers among people, which is being aided by government campaigns. With an eye towards improving rates of cancer survival, there is encouragement from the government for regular checkups and treatment. Government initiatives are also helping the research and development activities in the non-melanoma skin cancer industry.

Report Attributes	Details
Estimated Market Value (2024E)	US$ 5,068.7 million
Forecasted Market Value (2034F)	US$ 8,859.6 million
Global Market Growth Rate (2024 to 2034)	5.7% CAGR
Radiation Therapy Segment Growth Rate (2024 to 2034)	5.6%
Basal Cell Carcinoma Segment Growth Rate (2024 to 2034)	6.8%
North America Market Share (2024)	58.0%
East Asia Market Share (2024)	0.8%
Key Companies Profiled	Amgen Inc. Regeneron Pharmaceuticals Inc. Almirall Boehringer Ingelheim International GmbH Bristol-Myers Squibb Company Hoffmann-La Roche Ltd GlaxoSmithKline Plc Merck & Co., Inc. Novartis AG Eli Lilly and Company Sun Pharmaceutical Industries Ltd.

Which Factors are Driving the Non-melanoma Skin Cancer Market?

“Convenient Radiation Therapy Machines Ease Treatment Processes for Non-melanoma Skin Cancer Patients”

Radiation therapy is one of the most popular types of treatment when it comes to non-melanoma skin cancer. With the rising number of people undergoing radiation therapy, market players are focusing on producing machines that can increase the comfort of patients. The development of portable radiation machines ensures that patients do not have to strictly be confined to a singular bed while receiving treatment.

“Integration of New Technologies into Devices Used for Treatment”

Therapies used for the treatment of non-melanoma skin cancer are getting updated with the integration of cutting-edge technologies. Newly developed therapies such as stereotactic body radiation therapy (SBRT) and spatially fractionated radiation therapy (SFRT) concentrate on minimizing the side effects of the procedure, while general technology like AI is also being implemented for purposes such as diagnostic assistance and quality assurance. Thus, the integration of technology is making sure the market demand remains fresh.

What are the Challenges Encountered by Market Players?

“Aversion Towards Side Effects, as well as the High Price Involved, Makes People Skeptical of Non-melanoma Skin Cancer Treatment”

The treatments for non-melanoma skin cancer, such as radiation therapy and chemotherapy, come with side effects. Hair loss, skin peeling, and anemia are some of the potential side effects of therapies used to treat non-melanoma skin cancer. Thus, despite the necessity of treatment, many people are hesitant about it. The high price of the treatment is another impediment to the growth of the market.

Several market players are coming up with measures to combat these restraints. The development of new forms of therapy is concentrated on minimizing the side effects associated with the treatment. Cheaper treatment options are also being made available with government aid. Nonetheless, the market still has to face significant challenges over the forecast period.

Country-wise Insights

North America accounts for an overwhelming share of the non-melanoma skin cancer market. Even though the share in the market is predicted to decrease over the forecast period, North America is still a lucrative region in the industry. In 2024, the value of the market in North America is estimated to be US$ 2,941.0 million, for a market share of 58.0%. The market is expected to progress at a CAGR of 2.9% from 2024 to 2034. By 2034, the industry value for North America is projected to reach US$ 3,930.0 million, with a market share of 44.4%.

The non-melanoma skin cancer market in East Asia is expected to progress at a faster pace than in North America. In 2024, the industry share for East Asia is projected to be 0.8%, with a market value of US$ 40.0 million. The market is expected to register a CAGR of 5.6% over the forecast period. By 2034, the market value in East Asia is anticipated to reach US$ 78.0 million, with an increased market share of 0.9%.

What Makes Mexico a Promising Country in the Non-melanoma Skin Cancer Market?

“High Number of Patients with Skin Cancer in Mexico”

Attribute	Detail
Market Value in 2024	US$ 14.0 million
CAGR (2024 to 2034)	8.1%

Mexico is set to be one of the most promising countries for the non-melanoma skin cancer industry. While the market value in Mexico is estimated to be US$ 14.0 million in 2024, it is projected to rise at a CAGR of 8.1% over the forecast period. By 2034, the value of the market is forecasted to rise to US$ 29.0 million.

Increased amounts of exposure to the sun have led to a rise in the number of people getting skin cancer in Mexico. With increasing global warming levels, the heat in the external environment is rising and the number of people at risk of skin cancers, both melanoma and non-melanoma, is also surging. Thus, treatment for non-melanoma skin cancer is being increasingly sought in Mexico.

Why is China Emerging as a Lucrative Country for Market Players?

“Considerable Population of China Prone to Cancers, Including Non-melanoma Skin Cancer”

Attribute	Detail
Market Value in 2024	US$ 27.0 million
CAGR (2024 to 2034)	7.0%

China is one of the most lucrative Asian countries in the non-melanoma skin cancer industry. The market valuation is anticipated to be US$ 27.0 million in 2024. From 2024 to 2034, the market is expected to progress at a CAGR of 7.0% through 2034. The market valuation is expected to reach US$ 53.0 million by 2034.

China is claimed to be the country with the highest number of cancer patients as well as cancer deaths in Asia. As a result, there is a growing drive to protect the Chinese population from cancer. Treatments like non-melanoma skin cancer therapy are, therefore, receiving a boost in the country in terms of research and public investment.

Category-wise Insights

Radiation therapy is the most common type of therapy administered, with an expected market share of 88.6% in 2024. The second most popular type of therapy is photodynamic therapy, which is expected to account for 8.6% of the market share in 2024. By indication, the basal cell carcinoma segment is leading the market, with an expected industry share of 75.7% in 2024. Squamous cell carcinoma is expected to account for the remaining 24.3%.

Which is the Highly Preferred Mode of Treatment for Non-melanoma Skin Cancer?

“Success of Radiation Therapy in Treatment of All Cancer Types”

Attribute	Detail
Market Share in 2024	88.6%

Radiation therapy leads the treatment type segment, with an anticipated market share of 88.6% in 2024. The product is expected to register a CAGR of 5.6% over the forecast period. By 2034, the share of radiation therapy in the treatment type segment is expected to be 87.4%.

Radiation therapy is the go-to option for many healthcare experts. It has proven itself to be an effective form of treatment for a variety of cancers. The confidence placed in radiation therapy extends to the treatment of non-melanoma skin cancer. Thus, radiation therapy is the dominant form of treatment in the market.

Competitive Landscape

As a way to make treatments more effective, companies are investing heavily in research and development. Market players are also augmenting research efforts by collaborating with research institutes and universities and providing them financial aid.

Market players are taking advantage of public campaigns to raise awareness of non-melanoma skin cancer. Widespread advertising campaigns are being engineered to increase check-up and treatment numbers.

Key players in the market include Amgen Inc., Regeneron Pharmaceuticals Inc., Almirall, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Merck & Co., Inc., Novartis AG, Eli Lilly and Company, and Sun Pharmaceutical Industries Ltd.

Recent Developments :

• In November 2023, DermaSensor announced that its AI-powered elastic scattering spectroscopy (ESS) device showed positive results in the detection of skin cancers.
• In August 2023, SkinCure Oncology was made available in the American state of Kentucky. SkinCure Oncology provides Image-Guided Superficial Radiation Therapy (Image-Guided SRT), a non-surgical way of treating skin cancers.
• In June 2023, it was announced that Sirnaomics Ltd.’s siRNA treatment for squamous cell carcinoma had advanced to phase 3 of its trial after positive phase 2 results.

Segmentation of Non-melanoma Skin Cancer Market Research

• By Treatment Type :

  • Radiation Therapy
  • Chemotherapy
  • Photodynamic Therapy

• By Indication :

  • Basal Cell Carcinoma
  • Squamous Cell Carcinoma

• By End User :

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics

• By Region :

  • North America
  • Europe
  • Latin America
  • East Asia
  • South Asia & Oceania
  • Middle East & Africa